在肝细胞癌的辅助性和新辅助性免疫疗法
Josep M Llovet1,2,3, Roser Pinyol4, Mark Yarchoan5,6
1Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain. josep.llovet@mountsinai.org.
辅助性阿特佐利祖马布加贝瓦齐祖马布在切除后对高风险早期肝癌 (HCC) 患者的无复发生存益处. 这为治疗治疗后的HCC复发提供了新的策略.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 肝细胞癌研究 肝细胞癌研究
背景情况:
- 肝细胞癌 (HCC) 是全球癌症死亡的主要原因.
- 虽然早期的HCC提供了治疗选择,但切除或切除后的复发率很高 (高达70%).
- 现有的辅助疗法在预防HCC复发方面取得了有限的成功.
研究的目的:
- 审查目前对早期HCC的管理策略.
- 探索瘤免疫微环境和免疫检查点抑制剂 (ICI) 在HCC中的作用.
- 总结新辅助和辅助疗法在早期HCC的证据.
主要方法:
- 对当前的HCC管理进行全面审查.
- 对瘤免疫微环境和ICI机制的分析.
- 对新辅助和辅助HCC治疗的II/III期试验数据的摘要.
主要成果:
- 在高风险HCC患者中,IMbrave 050试验证明了辅助性阿特佐利祖马布加贝瓦齐祖马布的无复发生存益处.
- 新辅助性ICI也在早期HCC中表现出有效性.
- 在切除或切除后,对于有效的辅助疗法存在重大未满足的需求.
结论:
- 辅助剂阿特佐利祖马布加贝瓦齐祖马布代表了预防HCC复发的有希望的方法.
- 对新辅助和辅助免疫疗法的进一步研究至关重要.
- 生物标志物识别和优化临床试验设计是未来HCC治疗开发的关键.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
